2022
Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection
Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Berstam F, Mills GB, William W, Myers JN, Pickering CR. Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection. Clinical Cancer Research 2022, 28: 2796-2806. PMID: 35443062, DOI: 10.1158/1078-0432.ccr-21-3239.Peer-Reviewed Original ResearchOral squamous cell carcinomaProgression-free survivalSquamous cell carcinomaSurgical resectionCell carcinomaTreatment-related adverse event ratesAdvanced oral squamous cell carcinomaMajor pathologic response rateNeck squamous cell carcinomaPathologic response ratePlatinum-taxane chemotherapyCycles of chemotherapyAdverse event ratesMajor pathological responseExcellent clinical outcomesAddition of erlotinibCycles of treatmentPre-treatment samplesConcurrent erlotinibErlotinib armNeoadjuvant erlotinibInduction chemotherapyNeoadjuvant chemotherapySecondary endpointsDefinitive surgery
2020
Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma
Gleber‐Netto F, Neskey D, de Mattos Costa A, Kataria P, Rao X, Wang J, Kowalski LP, Pickering CR, Dias‐Neto E, Myers JN. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma. Cancer 2020, 126: 4498-4510. PMID: 32797678, DOI: 10.1002/cncr.33101.Peer-Reviewed Original ResearchConceptsAdvanced oral squamous cell carcinomaOral squamous cell carcinomaExtranodal extensionSquamous cell carcinomaTP53 mutationsAncillary biomarkersCell carcinomaCancer Genome Atlas (TCGA) cohortPostoperative adjuvant therapyTP53 mutation statusWild-type TP53Adjuvant therapyCancer Genome AtlasCommon genetic eventClinicopathologic characteristicsClinical outcomesP53 protein functionPatient managementTreatment decisionsClinical challengeTherapeutic approachesPatientsMutation statusHeterogeneous groupIncreased chance